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Abstract
Background: A malignant fibrous histiocytoma is a soft tissue tumor that most commonly occurs in the
extremities, but rarely involves the liver. The clinical characteristics and therapeutic experiences of primary hepatic
malignant fibrous histiocytoma are still limited.
Methods: Two cases of primary hepatic malignant fibrous histiocytoma were analyzed retrospectively, and all the
literature concerning primary hepatic malignant fibrous histiocytoma was analyzed.
Results: In China, a total of 76 cases had been reported, among which 50 were men, with a male to female ratio
of 1.9:1. Mean age of the patients was 51.0 years old, and more than 85 percent were older than 40 years. 82.9
percent (63/76) of hepatic MFH were solitary lesions, with tumor size ranging from 2.5 to 23.5 cm (average 10.3
cm). Major clinical presentation (78.4%) was abdominal pain or discomfort, accompanied with some other non-
specific symptoms such as malaise, anorexia, weight loss, jaundice and fever, and small cases (14.9%) were
asymptomatic. Computed tomography and ultrasound usually revealed the location of lesions. The rate of pre-
operative misdiagnosis was extremely high, and 14.9 percent of patients were even misdiagnosed as a benign liver
cyst, liver abscess or hematoma. Integrated resection was performed among the most cases (49/68), among which
only a few ones (12 cases) were introduced to have no recurrence or metastasis or be still alive with no detail
information provided, while among the cases with palliative operation or only a biopsy, the cases that were
followed-up all died.
Conclusions: Hepatic malignant fibrous histiocytoma is a rare malignant mesenchymal tumor. The variable features
of clinical presentations and images make the diagnosis difficult. Though the prognosis of primary hepatic
malignant fibrous histiocytoma was rather poor, integrated resection might provide a few cases a good
opportunity for surviving, suggesting that surgery might be an effective treatment.
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Background
Since its initial description in 1964 by O’Brien and Stout
[1], malignant fibrous histiocytoma (MFH) has been
regarded as one of the most common soft tissue sarco-
mas of late adult life[2]. MFH primarily occurs in the
extremities and less commonly involves the retroperito-
neal spaces, abdominal cavity, or other sites [3]. The pri-
mary hepatic MFH is extremely rare, and there is still an
incomplete understanding of the clinicopathology of
primary hepatic MFH. In this study, two cases of pri-
mary hepatic MFH treated in our hospital are reported,
and the literature of Chinese cases before June 2011 was
reviewed and analyzed, to provide a better understand-
ing of the clinicopathologic characteristics of this rare
entity with an emphasis on its clinical characteristics
and therapeutic experiences.
Materials and methods
Clinical records of two patients with primary hepatic
MFH treated from 2006 to June 2011 at the Shengjing
Hospital of China Medical University were
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both patients, and the diagnosis was pathologically con-
firmed. Both of the patients were males, and their ages
were 56 and 62 years old respectively. Routine preopera-
tive examinations (physical examination, blood tests,
ultrasonography, CT and/or MRI) and relevant tumor
marker tests (A-fetoprotein, carcinoembryonic antigen
and/or CA 19.9) were performed. One patient was fol-
lowed up, while the other was lost.
China Academic Journal Full-text Database (CNKI),
Chinese Scientific Journals Database (VIP) and Wan
fang Database were used for searching Chinese reports
about hepatic MFH before June 2011. Articles from the
same institution were carefully studied to avoid the
repetitive adoption of the saved material, and 50 articles
including 91 cases were found.
A database including age, gender, symptoms, location,
size of the tumor, metastasis or invasion of adjacent tis-
sues, treatment and prognosis was created with all
patients’ characteristics. Every case that had at least six
of these eight elements was characterized as well-docu-
mented. All of the non well-documented cases were
excluded. 42 articles including 74 well-documented
cases of primary hepatic MFH were left. Among the 74
cases, 3 cases were excluded because they were diag-
nosed as myxoid MFH which was no longer a subtype
of MFH according to the 2002 WHO classification [4].
In addition, in the English literature, a total of 45
reported cases of primary hepatic MFH were found
[5-31] (Table 1). Among the 45 cases, 8 cases were from
China, and the related information of 5 cases in these 8
cases was also introduced in the Chinese literature. So
finally, including 2 cases in our hospital, 76 cases of pri-
mary hepatic MFH in China were included in this
review and analysis.
Results
Characteristic Features of Our Study Patients
Case 1
A 56-year-old man presented with discomfort in the
right upper abdominal quadrant, nausea, without weight
loss. Physical examination revealed a soft, non-tender
abdomen. Ultrasonography (Figure 1A, B) revealed a
hypoechoic mass with unmarked arrangement in the
right posterior lobe. The echogenicity was inhomoge-
neous, and color Doppler study showed no pulsative
flow signals, suggesting low vascularity in the mass.
N o n - e n h a n c e m e n tC T( F i g u r e1 C )s h o w e dah e t e r o g e -
neous mass with areas of cystic changes in the right
lobe. The size of the lesion was 6.8 × 6.6 cm, and the
lesion was ill demarcated with the surrounding hepatic
parenchyma. On contrast enhancement CT (Figure 1D-
F), solid components showed slight enhancement, while
the cystic components were never enhanced. Laboratory
data showed that the liver function tests were all within
normal ranges. HBsAg and HBcAb were positive. Levels
of alpha-fetoprotein (AFP), carcinoembryonic antigen
(CEA) and carbohydrate antigen 19-9 (CA 19-9) in
serum were all within normal limits. Ultrasound-guided
needle biopsy was performed, but the histopathological
findings were only necrotic tissues. Pre-operative diag-
nosis was hepatic neoplasm, and local resection of the
right lobe was performed. The surgical specimen mea-
sured 8 cm, and the mass was mostly solid, brown and
partially white in colour, with focal necrotic and hemor-
rhagic foci. The pathological diagnosis was primary
hepatic pleomorphic storiform MFH. Immunohisto-
chemically, the tumor cells showed positive for vimen-
tin, while stains for CK, EMA, Calponin, CD34, AFP,
hepatocyte and S-100 were all negative. The patient has
been followed up for 6 months to date, and is still alive,
without a recurrence.
Case 2
A 63-year-old man presented with intermittent twinge
pain in the right upper abdominal quadrant for 10 days,
without radiating pain, fever or weight loss. Physical
examination on admission revealed that abdomen is flat
and soft, and tenderness was in right upper abdomen,
without rebound tenderness. Liver and spleen was
untouched. MRI examination (Figure 2A-F) revealed a
mass that was ill delineated from surrounding liver par-
enchyma, and the main signal intensity of the mass was
hypo-intense compared with the liver, similar to that of
skeletal muscle on T1-weighted imaging. The main sig-
nal intensity of the mass on T2-weighted images was
higher than that in the liver, renal cortex or spleen. At
subsequent CT (Figure 2G-L), a heterogeneous multi-
nodular mass was confirmed, occupying the segment 6.
The mass was slightly enhanced during the arterial
phase of contrast enhancement, and the enhancement
was decreased during the portal and delayed phase.
Emission Computed Tomography (ECT) suggested that
there was no formation of bone metastasis. Laboratory
data showed a white blood cell count of 11.9 × 109/L,
hemoglobin level of 131 g/L and a platelets count of
179 × 109/L. The liver function tests were all within
normal ranges. Viral Hepatitis Testing revealed that
HBsAg and HBcAb were positive. Alpha-Fetoprotein
(AFP) was 1111.93 g/l (RR, < 25 g/l), and carbohydrate
antigenic determinant (CA 19-9) was 12.46 u/ml (RR, <
37 u/ml). Pre-operative diagnosis was hepatic neoplasm,
and the patient then underwent local resection of the
right lobe. The cut surface of the resected tumor
s h o w e dam u l t i - n o d u l ea p p e a r a n c ew i t hn e c r o s i s ,a n d
gray yellow in colour. The pathological diagnosis was
primary pleomorphic storiform MFH. Immunohisto-
chemically, the tumor cells showed positive for vimentin
and CD68, while stains for CK, CK8/18, CD35, CD21,
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Page 2 of 10Table 1 Clinical Features of 45 Cases of Primary Hepatic Malignant Fibrous Histiocytoma in the English literature
References/
Published
date
Authors No.
Cases
Age/
Sex
Presentation Location Size
(Largest
Dimension,
cm)
Therapy Follow-up/
Outcome
5 1985 Alberti-Flor et al 1 59/M Abdominal pain,
anorexia, low fever,
weight loss
Right and left
lobe
18 Surgery 2 w/died of
tumor
6 1985 Conran et al 1 61/M Abdominal pain,
anorexia, jaundice,
weight loss
Right and left 7 Puncture biopsy 18 d/died of
tumor
7 1986 Fukayama et al 1 38/F Hepatic mass Left lobe 7 Surgery 4 y/alive without
recurrence
8 1987 Arends et al 1 78/F Abdominal discomfort,
anorexia,shortness of
breath;
Right and left
lobe
> 10 Palliative 6 d/died of
tumor
9 1988 Bruneton et al 2 52/F Abdominal pain Right lobe 10 Surgery 2 y/alive without
recurrence
34/M Abdominal pain Right lobe 13 Palliative operation 6 mo/died of
tumor
10 1988 Honda et al 1 71/F Weight loss, fatigue,
fever
Right lobe > 10 Puncture biopsy,
chemoembolization
4 mo/died of
tumor
11 1988 Katsuda et al 1 61/M Abdominal discomfort Right lobe 8.5 Surgery and
chemotherapy
6 mo/died of
tumor
12 1991 Hamasaki et al 1 35/M Abdominal fullness,
palpable mass
Left lobe 9.1 Surgery, Intraarterial
therapy, later liver
transplant
34 mo/died of
lung metastasis
13 1992 Akifuji et al 1 79/M Anorexia, fatigue Left lobe 8 Chemoembolization,
Surgery
5 mo/recurrence
14 1992 Zornig et al 1 36/F Abdominal pain N/A 7 Surgery, postoperate
chemotherapy
63 mo/alive
without tumor
15 1992 McGrady et al 1 53/F Left-sided chest pain Left lobe 14
(operation)
Surgery, 5 years later
recured, surgery
again
9 y/alive without
tumor after
second surgery
16 1993 Reed et al 1 52/M Spike fever Right lobe > 10 Surgery, postoperate
chemotherapy
2 mo/died of
metastasis
17 1994 Pinson et al 1 41/M Abdominal pain,
weight loss
Right and left 11.5 Surgery 10 and a half
mo/died of
recurrence and
metastasis
18 1998 Fujita et al 1 70/M Malaise, anorexia,
fever, weight loss
Right and left 12 Puncture biopsy,
Surgery
3 mo/died of
tumor
19 1998 Wunderbaldinger
et al
1 56/F Palpable mass, lower
extremity swelling
Right lobe > 10 Surgery N/A
20
† 1998 Ferrozzi et al 3 62/F
† Abdominal pain,
malaise, low-grade
fever, and weight loss
Right lobe > 12 Surgery 3 y/alive without
recurrence
67/F Abdominal pain,
weight loss, malaise
and palpable mass.
Right and left > 12 Biopsy, palliative
chemotherapy.
N/A
69/M Abdominal pain,
weight loss, fatigue
and anorexia.
Right and left > 12 Puncture biopsy,
palliative
chemotherapy
N/A
21
† 1999 Yu et al 5 40-69
(53)/
4M,
1F
Abdominal
discomfort*4, right
shoulder and chest
pain*1
Right lobe *3,
left lobe *2
7-19 (mean
13)
Surgery*5 N/A*5
22 1999 Maekawa et al 1 68/M Malaise Right lobe 6 Surgery N/A
23 2005 Anagnostopoulos
et al
1 87/F Abdominal pain,
weight loss, low fever
Right lobe 12(CT) Puncture biopsy 6 mo/died of
tumor
24 2006 Ding et al 1 50/M Abdominal pain,
fatigue, weight loss
Right and left 14.2(CT) Biopsy after
laparotomy
2 mo/died of
tumor
Yao and Dai World Journal of Surgical Oncology 2012, 10:2
http://www.wjso.com/content/10/1/2
Page 3 of 10CD1a, S-100, HMB45, MelanA, SMA, LCA were all
negative. The patient was lost to follow-up.
Analysis of reports in China
Cases in China (including 2 patients in our series and 8
cases reported in the English literature)
Combined with the 2 patients in our series, 76 patients
in China have been reported (Table 2). Among the 76
patients, 50 were men, with a male to female ratio of
1.9:1. The mean age of the 71 patients which have a
clear age or mean age record was 51.0 years old (range,
10-77 years), and 88.1 percent (52/59) of the patients
were older than 40 years.
Most of hepatic MFH were large neoplasms, and only
13.2 percent (10/76) were smaller than 5 cm. The exact
sizes of hepatic MFH were mentioned in 59 cases,
including 19 cases with diameter descriptions in radiolo-
gical investigations. The mean diameter was 10.3 cm
(range, 2.5-23.5 cm).
Among the 76 cases, 82.9 percent (63 cases) of the
tumors were described as solitary lesions, while only 17.1
percent of the tumors were composed of multiple lesions.
The information of tumor localization was provided in 66
cases, including 10 cases with multiple tumor nodules.
Among the 10 cases, the tumor nodules of 4 cases were
found in both right and left lobes and the tumor nodules
of the remaining 6 cases were confined to one lobe of the
liver, 3 in the left and 3 in the right lobe. Among the 56
cases with a solitary lesion, tumors were often found in
the right lobe (33 cases), and less frequently in the left
lobe (21 cases), and the lesions of the remaining 2 cases
(3.6%) were in the middle part of the liver.
For clinical manifestation of hepatic MFH, 74 cases
provided details. The symptoms were usually non-
Table 1 Clinical Features of 45 Cases of Primary Hepatic Malignant Fibrous Histiocytoma in the English literature
(Continued)
25
‡ 2007 Ye et al 1 50/M Abdominal pain,
weight loss
Left lobe 16 Surgery 4 mo/died of
recurrence and
metastasis
26 2007 Chen et al 1 70/M Abdominal pain,
weight loss
Right lobe 12.4(CT) Palliative operation 1 mo/died of
tumor
27
† 2008 Li et al 7 77/F Spiking fever, weight
loss
Right lobe 10 Lobectomy 1 y/died of tumor
54/M Abdominal pain,
weight loss
Left lobe 5.5 Lobectomy 4 y/died of tumor
34/F Abdominal pain Right lobe 14 Liver and lung
Lobectomy
4 mo/died of
tumor
80/F Abdominal discomfort,
weight loss
Right lobe 20 Palliative 1 y/died of tumor
68/F Abdominal pain Right and left 2 N/A N/A
46/F Abdominal pain Right lobe 12 Gleevecineffective 3 mo/alive, tumor
larger but no
metastasis
70/
M
†
Incidental finding Right lobe 11 Lobectomy 4 y/no recurrence
28 2009 Sugitani et al 2 45/F Abdominal pain Left lobe 11 Surgery, 2 years and
5 months later
recured, surgery
again
34 mo/died of
tumor metastasis
70/F Jaundice Right lobe 12 Preoperate
chemotherapy,
Surgery
8 mo/died of
tumor metastasis
29 2009 Kim et al 1 60/M Abdominal pain,
weight loss
Right lobe 14 Surgery 41 mo/alive
without
recurrence
30 2010 Caldeira et al 1 63/M Abdominal discomfort,
lower extremities
edema and weight
loss.
Right lobe N/A Puncture biopsy 45 d/died of
tumor
31 2011 Cong et al 5 50-71
(59)/
2M,
3F
Abdominal pain or
discomfort*4, weight
loss*1
Right lobe *2,
left lobe *1, right
and left*1, N/A*1
2.5-16 Surgery*5 N/A*5
† indicates containing cases that were diagnosed as myxoid MFH; ‡ giant cell-type MFH
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pain or discomfort of different degrees, accompanied
with loss of body weight in 12 cases, obstructive jaun-
dice in 1 case, nausea and anorexia in 8 cases, and fever
in 15 cases, including 2 cases with the temperature
more than 39 degree. Nearly 14.9 percent (11 cases) of
the patients were asymptomatic, with the tumors found
during routine physical examinations or unrelated con-
ditions. In addition, 2 patients were admitted to hospital
for obstructive jaundice and 2 patients were for fever.
The last one patient was admitted for loss of body
weight and the lesion was found by the radiological
investigation on admission.
A variety of radiological investigations were performed
for the evaluation, including ultrasonography (US, 46
cases) and computed tomography (CT, 63 cases) in the
vast majority of the patients, and magnetic resonance
imaging (MRI) in only 16 patients. The tumors were
described on cross-sectional imaging as solid, cystic or
heterogeneous (solid and cystic) masses. Among the US
investigations of 46 cases, 34 cases provided details. The
tumors appeared hypoechoic in 10 cases, hyperechoic in
10 cases, anechoic in 2 cases, and showed a mixed pat-
tern that may include extensive necrotic areas in 8
cases. In addition, the tumors were described as cyst-
like lesions in 2 cases. Among the remaining 2 cases,
t h el e s i o n so fo n ec a s ew e r en o td e t e c t e da n dt h eo t h e r
case had a lesion in each lobe of the liver, a cyst-like
l e s i o ni nt h el e f tl o b ea n dah y p o e c h o i cl e s i o ni nt h e
right. We have detail CT descriptions of 49 cases. The
lesions that were not detected in the US investigation
were not detected either in the CT investigation.
Another case had one lesion in each lobe of the liver, a
hypodense mass in the left lobe and a cyst-like lesion in
the right. Among the remaining 47 cases, on plain CT
scanning, MFH appeared as hypodense masses with
necrotic areas of differing degrees in 40 cases, cyst-like
masses in 4 cases, mixed masses in 3 cases. 45 cases
provided details on the enhancement scanning. The
solid components or the cystic walls of 41 cases were
introduced to be variably enhanced, from slightly to
markedly, while the masses of the remaining 4 cases
showed no enhancement. Among the 16 cases with MRI
examinations, 2 cases provided no information of T1-
weighted MR images. The T1-weighted MR images of
the remaining 14 cases all showed low signal-intensity
masses. T2-weighted MR images of all the 16 cases
showed high signal-intensity solid masses. 11 cases pro-
vided details on contrast-enhanced dynamic MR images.
A gradual enhancement of internal components was
present in 10 cases, and no obvious enhancement was
showed in only 1 case.
For laboratory examinations, 5 cases provided no
details. It showed that 77.8 percent (35/45) of liver func-
tion tests and 60.8 percent (31/51) of hepatitis investiga-
tions were normal in the patients. About the tumor
marker, only a few of patients have slightly elevated
tumor marker levels, such as serum alpha-fetoprotein
(AFP, 7/68), carcinoembryonic antigen (CEA, 1/41), car-
bohydrate antigen 19-9 (CA19-9, 3/34). 5 cases have the
Figure 1 A 56-year-old man with abdominal discomfort. (A, B) Abdominal sonography revealed a hypoechoic mass with low vascularity. (C)
Non-enhancement CT showed a heterogeneous hypodense mass with areas of cystic changes in the right lobe. (D- F) After the contrast
injection, the mass was slightly enhanced, especially on the edge.
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nations and only 1 patient has an elevated level.
Despite the technological advances, pre-operative diag-
nosis of hepatic MFH is still difficult, and the rate of
misdiagnosis is extremely high. We had information
about preoperative diagnosis for 67 patients, none of
which, including one case with puncture biopsy before
operation in our series, got the exact diagnosis. 48 cases
were diagnosed as hepatic neoplasms, 8 cases were only
diagnosed as masses of liver. In addition, 10 cases
(14.9%) were even misdiagnosed as benign lesions of the
liver, including hemangioma in 3 cases, hepatophyma in
5 cases, hepatic hydatid cyst in 1 case and hepatic cyst
in 1 case. The remaining 1 case was only diagnosed as
calculi of intrahepatic duct, and the hepatic mass was
not discovered until surgery.
Surgical procedure was the main treatment for hepatic
MFH (Table 3). Among the 68 patients whose treat-
ments were available, 49 cases (72.1%) had integrated
resection, 4 cases (5.9%) had palliative operation (local
resection), 7 cases had (10.3%) puncture biopsy, and the
other 8 cases (11.8%) were found unresectable at
Figure 2 A 63-year-old man with abdominal pain. (A-C) MR images revealed a mass with low signal intensity on T1-weighted imaging and
high signal intensity on T2-weighted imaging. (D-F) The periphery of the mass was slightly enhanced during the arterial, portal or delayed
phase of contrast enhancement. (G) On CT, a heterogeneous hypodense mass was revealed. (H-L) After contrast material injection, the mass
showed gradual, inhomogeneous enhancement, with decreased enhancement on delayed scans.
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integrated resection, a lesion in the lung was also
detected synchronously with the one in the liver, and
left pneumonectomy was performed 50 days after opera-
tion. The lesion of the lung was demonstrated as meta-
static MFH and no adjunctive therapy was performed
afterward. Among the remaining 48 vases with inte-
grated resection, 3 cases received chemotherapy, 2 cases
received radiation therapy, 1 case received hepatic artery
and portal vein subcutaneous embedding alternate infu-
sion chemotherapy after operation, 1 case received hepa-
tic arterial infusion chemotherapy twice because of
tumor recurrence 2 months after operation, and 1 case
received lymphadenectomy and 125I radiation therapy
because of lymph nodes metastasis 3 months after
operation. Among the 4 cases with palliative operation,
1 case received intrahepatic dehydrated alcohol injection
and hepatic arterial chemoembolization six times and
regular antituberculosis treatment because misdiagno-
sised as intrahepatic nonspecific inflammatory granu-
loma, HCC or tuberculosis respectively before operation,
and after operation superselective arterial chemoemboli-
zation and hepaticarteriography chemoembolization
were also performed, another case received drainage
fenestrated with laparoscope because misdiagnosised
great cyst in the left lobe of liver before laparotomy, and
received palliative operation because of intraperitoneal
plant. Among the 7 cases with puncture biopsy, 1 case
received percutaneous cryoablation combined with
transarterial chemoembolization. Among the 8 cases
with biopsy after laparotomy, 2 cases received
chemotherapy.
Most cases of primary hepatic MFH were the type of
pleomorphic storiform MFH. One case in the Chinese
literature was the type of inflammatory MFH, which has
n o tb e e nr e p o r t e di nt h eE n g lish literature. In the Eng-
lish literature, the only case that was diagnosed as giant
cell MFH was also from China. For immunohistochem-
ical investigations, only 28 cases provided details. Immu-
nohistochemically, the tumor cells showed typically
positive for Vimentin(27/27), CD68(13/13), and
Table 2 Clinicopathological characteristics of primary hepatic malignant fibrous histiocytoma
Number of patients Percentage (%)
Sex 76
Male 50 65.8
Female 26 34.2
Age (years) 59
Older than 40 years 52 88.1
Yonger than 40 years 7 11.9
Clinical presentation 74
Abdominal pain or discomfort of differing degrees 58 78.4
Asymptomatic 11 14.9
Obstructive jaundice 3 4.1
Fever 17 22.8
Loss of body weight 13 17.6
Nausea and anorexia 8 10.8
Location 66
Left lobe 24 36.4
Right lobe 36 54.5
Right and left lobe 6 9.1
Diameter (cm) 76
Larger than 5 cm 66 86.8
Smaller than 5 cm 10 13.2
Table 3 Treatment and prognosis of primary hepatic
malignant fibrous histiocytoma
Number of patients
Treatment 68
Integrated resection 49
Palliative operation (local resection) 4
Puncture biopsy 7
Biopsy after laparotomy 8
Follow-up 42
†
Recurrence or metastasis within a year 10
Recurrence or metastasis over a year 2
No recurrence or metastasis within a year 5
No recurrence or metastasis over a year 2
Died 16
‡
Alive 6
† including one case that was lost after finding the lesion was increasing 4
month after operation. ‡ including 15 cases that died within a year and one
case that died without the surviving time provided.
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(10/12) showed positive in most cases. AFP(5/5), FVIII
(2/2), CEA(4/4), EMA(9/9), CK8/18(7/7), Hep parl(4/4),
CD10(3/3), HMB-45(7/7), Actin(5/5), Desmin(13/13)
showed all negative, and CK(1/12), CD34(1/5), S-100(1/
10), SMA(1/5) were expressed only in a few tumors.
To our knowledge, follow-up periods ranging from
one month to 10 years were mentioned for 42 patients.
The 8 cases with no treatment introduction have no fol-
low-up either. Among the 49 cases with integrated
resection, a postoperative follow-up was conducted in
33 patients. 10 cases of these 33 patients had recurrence
or metastasis within a year, 2 cases had recurrence or
metastasis over a year, 5 cases had no recurrence or
metastasis within a year, 2 cases had no recurrence or
metastasis over a year, 8 cases died within a year, and
the remaining 6 cases were still alive with no detail
information provided (the follow-up periods of these 6
cases was 1 month, 3 months, 23 months, 26 months, 3
years and 10 years respectively). Among the 4 cases
with palliative operation, 2 cases were followed-up. 1
case died of multiple organ failure 2 months after opera-
tion, and the other was lost after finding the lesion was
increasing 4 month after operation. Among the 7 cases
with puncture biopsy, 2 cases were followed-up, and
died 1 month and half of 1 month respectively after dis-
charge from hospital. Among the 8 cases with biopsy by
operation, 5 cases were followed-up. 4 cases died 1
month, 2 month, 3 month and half of 1 year respectively
after discharge from hospital, and 1 case died without
the surviving time provided.
Discussion
Malignant fibrous histiocytoma (MFH) was first
reported in 1964 by O’Brien and Stout[1] and has been
considered to be one of the most common soft tissue
sarcomas of late adult life[2]. Based on its morphological
pleomorphism, five histologic subtypes of MFH were
described by Enzinger and Weiss: pleomorphic stori-
form, myxoid, giant cell, inflammatory, and angiomatoid
[2]. Now, according to the current WHO classification,
myxoid MFH and angiomatoid MFH are no longer the
subtypes of MFH, and the terms myxofibrosarcoma and
angiomatoid fibrous histiocytoma are used for them.
Myxofibrosarcoma has been reallocated from the fibro-
histiocytic category to the myofibroblastic list and angio-
matoid MFH is now classified under the category of
tumors of uncertain differentiation [32].
MFH primarily occurs in the extremities and less
commonly involves the retroperitoneal spaces, abdom-
inal cavity, or other sites [3]. Primary hepatic MFH is
exceedingly rare, especially in comparison with MFH of
other sites, or with the more common primary malig-
nancies of the liver [2,33]. Since its original description
in 1985[5], to date, only 45 cases have been described in
the English literature, including recent reports by Li et
al. [27], Sugitani M et al. [28], Kim HS et al. [29], Cal-
deira A et al. [30] and Cong Z et al. [31]. Among the 45
cases, 8 cases were from China [24-26,31]. In the Eng-
lish literature, Li et al presented a series of 7 cases of
primary hepatic MFH (including one case that was clas-
sified as myxoid type), which is the largest series to
date. In our study, we review all well-documented
reported cases of hepatic MFH in China before June
2011, and the largest series in the Chinese literature
include 11 cases, among which one case was also classi-
fied as myxoid type. The cases of primary hepatic MFH
were mostly the type of pleomorphic storiform. One
case in the Chinese literature was the type of inflamma-
tory MFH, which has not been reported in the English
literature. In addition, in the English literature, the only
case that was diagnosed as giant cell-type MFH was also
from China.
For epidemiological characteristics of hepatic MFH,
our study confirms previous reports on this neoplasm as
a malignant entity, often with a large mass and predomi-
nantly affecting adult patients. However, there are also
some differences in our study with previous ones. In the
previous study in the English literature, patients were all
older than 34, whereas in our study it is found that
there are also 4 patients younger than 15 years old,
including 1 boy and 3 girls, suggesting that the primary
hepatic MFH could also occur among young persons. In
addition, in a recent study of 34 cases, Li and colleagues
showed that there was no sex predilection in the hepatic
MFH[27], while in our study, 50 of 76 patients in China
were men, with a male to female ratio of 1.9:1, suggest-
ing that there might be a slight male predominance for
the incidence of this rare malignant tumor. Certainly,
these results still waits further confirmed in the future
study.
The clinical presentation of primary hepatic MFH is
nonspecific, including abdominal pain or discomfort,
systemic symptoms of low-grade fever, malaise, anor-
exia, jaundice and weight loss, and nearly 14.9 percent
(11 cases) of the patients in our study were asympto-
matic. Spiking fever might also be a clinical presenta-
tion, such as 2 cases in the study of Li and colleagues
[27], and 2 cases in our study. Consistent with previous
studies, our study also confirms that radiological investi-
gations of primary hepaticM F Ha r ev a r i o u sa n dn o n -
specific. The lesions could be homogeneous solid [21],
heterogeneous dense with areas of necrosis or nearly
complete cystic changes [29] in the ultrasonography
(US), CT or MRI examinations. After contrast adminis-
tration, the solid components or the cystic walls mostly
demonstrate variable enhancement. Delay enhancement
can be observed and the intensity depends on the
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the lesions were usually detected and located by radiolo-
gical investigations, specially, 1 case that was diagnosed
as inflammatory MFH by biopsy was misdiagnosed only
as calculi of intrahepatic duct before surgery, and the
multiple hepatic masses in the left lobe of liver were not
discovered until surgery. Laboratory examination also
lack available and helpful indexes for preoperative diag-
nosis. 77.8 percent (35/45) of liver function tests and
60.8 percent (31/51) of hepatitis investigations were nor-
mal and the negative percentage of serum alpha-fetopro-
tein(AFP), carcinoembryonic antigen (CEA), CA19-9
and CA125 were all rather high, suggesting these tumor
markers were not suitable predictors for this malignant
hepatic tumor either.
Duo to the lack of the specification for the clinical
presentations, images or tumor markers, the pre-opera-
tive diagnosis of hepatic MFH was rather difficult and
the rate of pre-operative misdiagnosis was extremely
high. In our study, none of the patients got the exact
diagnosis. In addition, 10 cases (14.9%) were even mis-
diagnosed as benign lesions of the liver, including
hemangioma, hepatophyma, hepatic hydatid cyst and
hepatic cyst. The misdiagnosis may usually make the
effective treatment delayed, or even lead to error treat-
ments, especially for the hepatic MFH with cyst masses.
1 case in our study received drainage fenestrated with
laparoscope because misdiagnosised as a great cyst in
the left lobe of liver before laparotomy, and afterward
the patient received only palliative operation because of
intraperitoneal plant, which might be caused by the
drainage.
Surgical resection with negative resection margins is
the mainstay of treatment for primary MFH of the liver.
Though the prognosis of hepatic MFH is poor, there are
still some cases with good prognosis and one case in
our study was even alive 10 years after resection of the
lesion. In the study of Li et al, it was also showed that
up to 33% of patients survived for more than 2 years
[27]. So, early diagnosis and effective treatment might
be an effective method. Furthermore, repeated surgery
after recurrence might be also effective [15,28]. Besides,
consistent with previous studies, our study also suggests
that adjunctive therapies, such as chemotherapy che-
moembolization or radiation therapy, are not effective
treatment for this rare tumor. In addition, one thing to
be noted is that the patients with incomplete surgery or
biopsy seem to have a worse prognosis. In our study,
among the cases with palliative operation or only a
biopsy, 9 cases were followed-up and there were 7 cases
that died within half a year after discharge from hospi-
tal, 1 case that died without the surviving time provided
and 1 case that was lost after the lesion was found to
increase 4 month after operation. Moreover, none of the
8 cases that survived more than 2 years in the English
literature just received a biopsy [7,9,12,14,15,27-29].
Conclusions
Although hepatic MFH is a rare malignant mesenchymal
tumor, it should also be considered in the diagnosis of
large liver lesions. The features of clinical presentations
and images are variable and the pre-operative diagnosis
is difficult. Surgical resection is the most effective means
for treating this rare tumor. Though the prognosis is
poor, complete surgery with negative resection margins
might provide a few of cases a good opportunity for sur-
viving. Surgery again may be also useful for a recurrent
tumor.
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